Gabather AB engages in the research and development of drug candidates for treatment of diseases affecting the central nervous system. It focuses on anti-psychotics, anti-depressants and anxiolytics, analgesics and cognition-enhancing treatments. The company was founded by Bert Roland Kari Junno, Olov Arvid Sterner, Knut Mikael Ingolf Lindstam and Mogens Nielsen on November 3, 2014 and is headquartered in Sodertalje, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company